Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.36. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | EMLC | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Fixed Income |
52-Week High | $22.37 | $26.59 |
52-Week Low | $10.24 | $24.83 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EMLC trades at $25.59 with a modest 0.51% daily gain, showing bullish technical momentum with strong moving average support. The ETF maintains a consistent dividend distribution pattern with recent $0.14 payouts, while technical indicators show mixed signals with RSI in neutral territory. Emerging market debt remains in focus as investors seek yield above Treasury bonds amid shifting global monetary policy.
The outlook for EMLC hinges on Federal Reserve policy and emerging market stability. The 6.09% yield provides income appeal, but currency risk and short interest growth present challenges. Institutional demand for EM debt is rising, though sustainability concerns warrant monitoring given the 73% short interest surge reported in April 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
